Retatrutide Dosage and Titration: What the Trials Used
Retatrutide Dosage: What the Phase 2 Trials Used
Retatrutide dosage in Phase 2 ran from 1 mg to 12 mg, once weekly, by subcutaneous injection. The standard ladder started at 2 mg and stepped up every four weeks. At the 12 mg ceiling, participants lost an average of 24.2% of body weight over 48 weeks. (Jastreboff 2023)
Retatrutide (LY3437943) is not approved for clinical use. Everything below comes from published trials. It reports what investigators used and why. It is not prescribing guidance.
For sourcing research peptides, see our recommended sources page.
Retatrutide Dosing: Why the Triple Mechanism Shapes the Schedule
Retatrutide switches on three receptors at once: GLP-1R, GIPR and GCGR. No approved obesity drug targets all three. That drives weight loss three ways. It curbs appetite, improves how the body handles glucose and fat, and raises energy burn.
The receptor balance is where the dosing logic starts. Retatrutide is one synthetic peptide with a fatty diacid chain attached. Its potency is deliberately lopsided. It binds GIPR at 8.9 times the strength of the body's own GIP. It binds GLP-1R at only 0.4 times, and GCGR at only 0.3 times. (Katsi 2025)
That imbalance is on purpose. Strong GIPR activity sharpens glucose control after meals and works with GLP-1R to curb appetite. The dialled-down GCGR signal lifts energy burn without pushing blood sugar too high. The result outperforms dual agonists like tirzepatide in early comparisons. (Doggrell 2023)
Retatrutide Dosage Schedule: The Phase 2 Dose Ladder
The Phase 2 trial enrolled 338 adults with obesity or overweight. They were randomised to 1, 4, 8 or 12 mg once-weekly retatrutide, or to placebo, for 48 weeks. The starting dose was 2 mg or 4 mg depending on the group. Steps came every 4 weeks.
The randomised, double-blind, placebo-controlled design was published in the New England Journal of Medicine in 2023. It set the dosing architecture still used today. (Jastreboff 2023)
| Parameter | What the trial used |
|---|---|
| Route | Subcutaneous injection (abdomen, thigh or upper arm) |
| Frequency | Once weekly |
| Maintenance doses tested | 1 mg, 4 mg, 8 mg, 12 mg |
| Starting dose | 2 mg (low-tolerability arm) or 4 mg (standard arm) |
| Step interval | 4 weeks at each dose before escalation |
| Duration | 48 weeks |
The choice between a 2 mg and a 4 mg start was not arbitrary. Investigators were testing whether a lower start cut the gut side effects. The answer was clear.
Retatrutide Starting Dose: Is It 2 mg or 4 mg?
Starting at 2 mg instead of 4 mg cut nausea from 60% to 17% in the 8 mg target group. The lower start did not cost any weight loss at 48 weeks. Slow titration is not optional. It is how most people reach and hold the higher doses.
This is one of the most useful findings in the whole Phase 2 programme. Gut side effects are the main tolerability problem for every drug in this class. Retatrutide is no exception. They cluster during dose increases and fade once a dose is held steady. (Jastreboff 2023)
The 2 mg start gives the gut four weeks to adapt before the first step up. The likely mechanism is gradual receptor desensitisation and a shift in how fast the stomach empties. People who pushed through a 4 mg start did not lose less weight in the long run. Many simply stopped early because the nausea during escalation was too much.
For anyone designing a protocol from this trial, 2 mg is the data-supported default.
Retatrutide Dosing Chart: The Full Phase 2 Ladder
Here is the ladder in full.
It ran 2 mg, 4 mg, 8 mg, then 12 mg as maintenance. Each step held for four weeks before the next. No step could be skipped.
| Weeks | Dose, once weekly | Stage |
|---|---|---|
| 1 to 4 | 2 mg | Starting dose |
| 5 to 8 | 4 mg | First step up |
| 9 to 12 | 8 mg | Second step up |
| 13 onward | 12 mg | Maintenance |
For anyone targeting 4 mg or 8 mg maintenance, the ladder stopped at that dose. The 1 mg arm used a single dose with no titration, because it sat below any escalation threshold.
Trial protocols let participants pause at the current dose for an extra four weeks if gut symptoms were significant. Dropping back to the last comfortable dose was allowed too. Neither move disqualified anyone, and neither appeared to cost weight loss. (Jastreboff 2023)
Retatrutide Dosage Chart for the Phase 3 TRIUMPH Ladder
The Phase 3 TRIUMPH programme enrolled over 5,800 participants. It refined the ladder to five steps: 2 mg, 4 mg, 6 mg, 9 mg, then 12 mg maintenance. Each is four weeks apart. The new 6 mg step smooths the Phase 2 jump from 4 mg to 8 mg.
| Weeks | Dose, once weekly | Change from Phase 2 |
|---|---|---|
| 1 to 4 | 2 mg | Same |
| 5 to 8 | 4 mg | Same |
| 9 to 12 | 6 mg | New intermediate step |
| 13 to 16 | 9 mg | New intermediate step |
| 17 onward | 12 mg | Maintenance |
TRIUMPH-1 and TRIUMPH-2 track weight management over 68-week primary windows. TRIUMPH-3 and TRIUMPH-4 nest sleep apnoea and knee osteoarthritis outcomes in the same framework. Maintenance doses across the programme are 4 mg, 9 mg and 12 mg. (Giblin 2025)
This five-step ladder is the most rigorous titration protocol published so far. The extra 6 mg step was almost certainly informed by Phase 2 tolerability data. In that trial, the direct 4 mg to 8 mg jump produced the most dose interruptions.
Retatrutide Dosage Per Week: What Each Dose Delivered
Weight loss rose with dose at every level tested. The 12 mg dose gave 24.2% mean weight reduction at 48 weeks. But 4 mg gave 17.1% and 8 mg gave 22.8%. Meaningful fat loss does not require the top dose.
| Weekly dose | Mean weight loss at 48 weeks |
|---|---|
| 1 mg | 8.7% |
| 4 mg | 17.1% |
| 8 mg | 22.8% |
| 12 mg | 24.2% |
| Placebo | 2.1% |
(Jastreboff 2023, Tewari 2025)
Look at the gap between 8 mg and 12 mg. It is 22.8% against 24.2%, a difference of 1.4 percentage points. Anyone who cannot tolerate going past 8 mg is not losing much. Pushing to the ceiling should follow individual response and tolerance, not a belief that the top dose is always better.
A 2025 systematic review and meta-analysis pooled four randomised trials. It confirmed the dose-response relationship and rated the evidence quality high. (Tewari 2025)
Retatrutide Half Life and Why Dosing Is Once Weekly
About 6 days.
That half-life is what makes once-weekly dosing rational. Steady-state levels arrive in 4 to 5 weeks at any dose. That is exactly why the ladder waits 4 weeks before each step.
The interval is not admin convenience. It is set by the drug's behaviour in the body. Step up before steady state and you are not judging the response to the current dose. You are judging a moving target. (Tetelbaun 2024)
| Measure | Value |
|---|---|
| Half-life | About 144 to 165 hours (~6 days) |
| Elimination | Dose-proportional across 1 to 12 mg |
| Steady state | 4 to 5 weeks at each dose |
| Washout | Meaningful levels persist about 30 days after the last dose |
| Route | Subcutaneous only; no oral form tested in humans |
The washout matters if a protocol is interrupted. This is not a short-acting drug where a missed dose drops the effect quickly. Retatrutide holds meaningful blood levels for four weeks after the last injection. A one-week gap is not a reset.
How to Reconstitute Retatrutide, and Retatrutide Dosage in ml
Research vials usually hold 5 mg or 10 mg of freeze-dried powder. Add 1 mL of bacteriostatic water to a 5 mg vial and you get 5 mg/mL. Each 0.1 mL drawn into a 100-unit insulin syringe then delivers 0.5 mg. Change the volume drawn and the dose scales with it.
Start with a 5 mg vial in 1 mL of bacteriostatic water. That gives 5 mg/mL.
| Dose | Draw | Units on a 100U syringe |
|---|---|---|
| 2 mg | 0.40 mL | 40 units |
| 4 mg | 0.80 mL | 80 units |
| 5 mg | 1.00 mL | 100 units (full vial) |
A 10 mg vial in 2 mL of bacteriostatic water also gives 5 mg/mL.
| Dose | Draw | Units |
|---|---|---|
| 2 mg | 0.40 mL | 40 units |
| 4 mg | 0.80 mL | 80 units |
| 8 mg | 1.60 mL | 160 units (needs a 2 mL syringe) |
| 9 mg | 1.80 mL | 180 units |
| 10 mg | 2.00 mL | Full vial |
For a 12 mg target, a 10 mg vial in 1 mL of bacteriostatic water gives 10 mg/mL. A 12 mg dose is then 1.20 mL per injection, which draws from two vials if you are using 1 mL syringes.
| Step | What to do |
|---|---|
| Adding the water | Run it slowly down the side of the vial, not onto the powder |
| Mixing | Swirl gently until dissolved. Do not shake |
| Storage | Refrigerate at 2 to 8 degrees Celsius |
| Shelf life | Use within 28 days; bacteriostatic water allows multi-dose use |
| When to discard | If the solution is cloudy or has visible particles |
Always work with a qualified clinician before changing your health protocol.
Liver Fat Outcomes: The MASLD Substudy
Liver fat responded harder than body weight did.
A Phase 2a substudy followed 98 participants with metabolic dysfunction-associated steatotic liver disease, meaning fat build-up in the liver. Liver fat fell with dose, from 42.9% at 1 mg up to 82.4% at 12 mg, measured at 24 weeks. Those drops are far larger than the weight loss at the same points, which suggests liver fat is a preferred target.
| Weekly dose | Liver fat reduction at 24 weeks |
|---|---|
| 1 mg | 42.9% |
| 4 mg | 57.0% |
| 8 mg | 81.4% |
| 12 mg | 82.4% |
(Harrison 2024, Harrison 2024)
The GCGR component is the likely driver here. Switching on GCGR pushes the liver to burn fatty acids and to make less new fat. The 8 mg dose reaches roughly the same liver fat reduction as 12 mg, at 81.4% against 82.4%. That plateau mirrors the weight loss plateau, and it arrives earlier.
How Much Retatrutide Should I Take, and How Do I Manage Side Effects?
Two things help, and both are in the trial data.
Gut side effects are the main tolerability issue, and they come mostly during dose increases. Nausea, diarrhoea, vomiting and constipation are the most reported. Slow titration and the 2 mg start are the two mitigations the trial data actually supports.
The systematic review confirmed that side effects rise with dose and sit in line with the wider GLP-1 and GIP class. (Tewari 2025) The single most useful number stays the start-dose comparison: 17% nausea against 60%, in the 8 mg target group. (Jastreboff 2023)
| If this happens | What the trial protocols allowed |
|---|---|
| Starting out | Use 2 mg, whatever the target maintenance dose |
| Before any step up | Hold the current dose for the full 4 weeks |
| Gut symptoms at the current dose | Pause escalation for another 4 weeks |
| Severe symptoms | Drop back to the last comfortable dose |
| After things settle | Try the step up again once the dose is stable |
No published trial shows that forcing a faster climb improves long-term weight loss. The 48-week results came from slow, methodical escalation. Speeding that up is not supported by the evidence.
How to Take Retatrutide: Where It Stands in 2026
Not approved anywhere yet.
Retatrutide is in Phase 3 TRIUMPH trials, with no regulatory approval from any major agency as of mid-2026. It remains available only as a research peptide outside clinical settings. Phase 3 readouts are expected across 2025 and 2026, with a possible filing window of late 2026 to 2027.
Where to source it
Research-grade retatrutide is available from verified suppliers. Always verify purity certificates before use.
See the sources that passed →TRIUMPH spans four trials and more than 5,800 participants, across weight management, sleep apnoea and knee osteoarthritis. (Giblin 2025) That breadth reflects how Eli Lilly, the developer, sees the compound: as a platform, not a single-indication drug.
For now the NEJM Phase 2 paper is the primary dosing reference. When the TRIUMPH Phase 3 papers land, they will supersede the Phase 2 ladder as the basis for any protocol.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023. doi:10.1056/NEJMoa2301972
- Tetelbaun L, et al. The First Triple Agonist for Antiobesity: Retatrutide. Cardiol Rev. 2024. PMID 39724554
- Harrison SA, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. PMC. 2024. PMC11271400
- Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2025. PMID 41090431
- Tewari J, et al. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2025. PMID 39817343
- Katsi V, et al. Retatrutide: A Game Changer in Obesity Pharmacotherapy. PMC. 2025. PMC12190491
- Doggrell SA. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023. PMID 37086147
- Harrison SA, et al. Triple hormone receptor agonist retatrutide for MASLD. Nature Medicine. 2024. doi:10.1038/s41591-024-03018-2
This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.
Related: Retatrutide Explained: How the Triple Agonist Actually Works
Where to source it
Research-grade retatrutide is available from verified suppliers. Always verify purity certificates before use.
See the sources that passed →Share this article
Frequently Asked Questions
What is the starting dose of retatrutide in clinical trials?
How fast should retatrutide dose be increased?
What is the maximum dose of retatrutide tested in trials?
How long does retatrutide stay in your system?
Why does slow titration matter for retatrutide tolerability?
Do patients need to reach 12 mg to achieve meaningful weight loss with retatrutide?
Read Next
Disclaimer: This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.